Sartorius Launches Novel High-Performance Octet R Series of Systems

The Octet R series makes use of the company's proprietary Bio-Layer Interferometry (BLI) technology, which employs optical biosensors to calculate molecular interactions without the use of detection agents simultaneously.

FREMONT, CA : The Life Science Group Sartorius launched the new high-performance Octet R series of systems, the latest improvement in its line of label-free analytical products. Users can select from three different models to find the best balance between throughput and budget. Field upgradeability would appeal to budget-conscious users; the Octet R2 and Octet R4 can be upgraded to an Octet R4 or Octet R8 within a single service visit to achieve higher throughput. In the biologics production workflow, all three systems can handle various applications and sample forms.

"Users of label-free applications in academia and at start-up biotech companies have historically been stuck between choosing to pay a premium for capacity they will never use or to settle for a lower-performance entry level system," said Payal Khandelwal, Head of Product Management, Protein Analysis, Sartorius. "The Octet R series is ideal for academic start-up and low volume labs that are looking for affordable, high quality, label-free capabilities without compromising on assay sensitivity. Plus, the flexibility to upgrade when throughput demands increase protects and futureproofs their investment."

The Octet R series makes use of the company's proprietary Bio-Layer Interferometry (BLI) technology, which employs optical biosensors to calculate molecular interactions without the use of detection agents simultaneously. For kinetic characterization of antibody, protein, and small-molecule binding interactions, all instruments provide an advanced, fast, stable, and fluidics-free approach. Even in complex mixtures and unpurified samples like cell culture supernatants and lysates, these systems allow direct detection of specific proteins and other biomolecules.

"Octet BLI has been an essential tool for customers developing novel drugs, therapeutics and biosimilars, providing more efficient and flexible assays for biomolecular interaction analysis," commented Payal. "We listened to our customers and are excited to launch the new Octet® R series of instruments with enhanced scalable throughput, assay and sample versatility. Our goal is to deliver innovative products that continually offer higher data quality to improve the outcomes of life science research and development projects."

Owing to the rapid speed of scientific advances and breakthroughs, laboratories worldwide are under pressure to generate high-quality, reproducible results on tight budgets and timelines. For over a decade, Octet BLI instruments have met these needs by offering fluidics-free, low-maintenance, and responsive systems. These systems improve lab efficiency, lower costs, and cut down on experimental time.

"With simplicity comes tremendous confidence and freedom to experiment and excel. At Sartorius, our goal is to accelerate research with this new expandable, modular, label free molecular analysis platform," said Payal. "As evidenced by over 5,000 peer reviewed publications, scientists are getting the results needed to progress research quickly and easily with the combined innovation, support and expertise of Sartorius Octet."

The Octet platform is a comprehensive characterization tool with unrivaled ease of use and cost-efficiency for various applications in drug and biologics production, including antibody and protein quantitation. It overcomes ELISA and HPLC platforms' drawbacks, allowing for more educated decisions earlier in the development process. Standard microplate formats are used in Octet systems, allowing for high-throughput, automated binding analysis directly in the plates. Since sample consumption during processing is low, valuable samples may be retrieved for future use.